TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03772691

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral suspension
Description: • The vesico-vaginal space was found between the bladder and the anterior vaginal wall in the fascia plane. A polypropylene mesh (25 , 25 cm, Ethicon, Inc., Somerville, NJ) was cut to obtain two long arms (15-20 mm wide) and a rectangular piece (4-7 cm wide).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sacropexy
Description: • The mesh is fixed on the anterior longitudinal ligament of sacrum with separated number 1 prolene sutures. The other end of the mesh is passed through the peritoneal tunnel and fixed to the cervix using prolene 1 and vicryl o sutures.
Study: NCT02771002

Intervention type: DEVICE
Intervention: Peripheral Perfusion index by Carescape Patientenmonitor
Description: Peripheral Perfusion index measured with pulse-oximetry by Carescape Patientenmonitor

Intervention type: DEVICE
Intervention: Peripheral Perfusion index by Carescape Patientenmonitor
Description: Peripheral Perfusion index measured with pulse-oximetry by Carescape Patientenmonitor

Intervention type: DEVICE
Intervention: Peripheral Perfusion index by Carescape Patientenmonitor
Description: Peripheral Perfusion index measured with pulse-oximetry by Carescape Patientenmonitor
Study: NCT02949869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Sonography
Description: As described previously
Study: NCT04307576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-tioguanine+Standard Maintenance Therapy
Description: Addition of p.o. 6-tioguanine to Standard Maintenance Therapy
Study: NCT04030611

Intervention type: DIAGNOSTIC_TEST
Intervention: tongue diagnosis system
Description: This study apply TCM diagnostic tools for clinical diseases, providing objective diagnostic data for evaluation to assess the association of blood stasis and DR.

Intervention type: DIAGNOSTIC_TEST
Intervention: tongue diagnosis system
Description: This study apply TCM diagnostic tools for clinical diseases, providing objective diagnostic data for evaluation to assess the association of blood stasis and DR.
Study: NCT04307576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: IV Blinatumomab
Study: NCT01539135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene Blue
Description: 20 cc methylene blue instilled above the cuff once after intubation for the duration of the surgical procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: 20 cc methylene blue instilled above the cuff once after intubation for the duration of the surgical procedure
Study: NCT01716689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral cyclophosphamide
Description: 50mg daily
Study: NCT01087489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% lidocaine
Description: The eye will be topically anesthetized with 0.5% proparacaine drops and 4% lidocaine drops and a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface followed in three rounds by additional 5% povidone iodine and a sterile cotton swab soaked in sterile 4% lidocaine applied with gentle pressure to the area designated for injection in the infero-temporal quadrant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.5% ophthalmic lidocaine gel
Description: The eye will be topically anesthetized with 0.5% proparacaine drops and 5% povidone iodine will be placed over the eye. Two drops of preservative-free 3.5% lidocaine hydrochloride ophthalmic gel will be placed into inferior conjunctival sac. The patient will be asked to close the eye for 7 minutes. Next, a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface and allowed to remain in contact with the eye for at least 2 minutes. The eye will then be rinsed with antibiotic drops.
Study: NCT02150135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncothermia
Description: Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.
Study: NCT02699684

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lenses with EOBO-41
Description: Lotrafilcon B contact lenses packaged with copolymer 845 and EOBO-41

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lenses with EOBO-41
Description: Lotrafilcon B contact lenses packaged with copolymer 845 and EOBO-41

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lenses
Description: Lotrafilcon B contact lenses packaged with copolymer 845

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lenses
Description: Lotrafilcon B contact lenses packaged with copolymer 845

Intervention type: DEVICE
Group type: OTHER
Intervention: Hydrogen peroxide-based lens care solution
Description: Commercially-available hydrogen peroxide-based lens care solution for cleaning, disinfecting, and storing silicone hydrogel soft contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Hydrogen peroxide-based lens care solution
Description: Commercially-available hydrogen peroxide-based lens care solution for cleaning, disinfecting, and storing silicone hydrogel soft contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Saline solution for rinsing contact lenses
Description: Commercially-available saline solution used as needed

Intervention type: DEVICE
Group type: OTHER
Intervention: Saline solution for rinsing contact lenses
Description: Commercially-available saline solution used as needed

Intervention type: DEVICE
Group type: OTHER
Intervention: Saline solution for rinsing contact lens case
Description: Commercially-available solution used as needed
Study: NCT02142855

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concentric Exercise Training
Description: 8 weeks concentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concentric Exercise Training
Description: 8 weeks concentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric Exercise Training
Description: 8 weeks eccentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric Exercise Training
Description: 8 weeks eccentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
Study: NCT00810043

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kyphon® Curette
Description: The Kyphon® Curette is intended to scrape and score bone in the spine. It may be used as an adjunctive device with Kyphon's family of standard access and fracture reduction instruments designed to treat compression fracture during balloon kyphoplasty procedures

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kyphon® Curette
Description: The Kyphon® Curette is intended to scrape and score bone in the spine. It may be used as an adjunctive device with Kyphon's family of standard access and fracture reduction instruments designed to treat compression fracture during balloon kyphoplasty procedures
Study: NCT02253940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 - Treatment A (current tablet formulation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 - Treatment B (new tablet formulation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 - Treatment C (new capsule formulation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 - Treatment D (current tablet formulation)
Study: NCT02699684

Intervention type: DEVICE
Group type: OTHER
Intervention: Saline solution for rinsing contact lens case
Description: Commercially-available solution used as needed
Study: NCT01113944

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program 1

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program 2
Study: NCT02925507

Intervention type: OTHER
Intervention: Swallowing Screen
Description: Patient will be ask to undergo a swallowing screen by study staff

Intervention type: OTHER
Intervention: Swallowing Screen
Description: Patient will be ask to undergo a swallowing screen by study staff
Study: NCT02253940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 - Treatment E (new capsule formulation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study: NCT01368952

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pure prone positioning
Description: Pure prone positioning device consisted of a pillow mounted on a table designed to keep the subjects sleeping prone.
Study: NCT03233711

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04123444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Continuously infusion for 72 hours. treatment dose 1 ng/kg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: Continuously infusion for 72 hours.
Study: NCT01507571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Description: Dignity Therapy is a brief psychotherapeutic intervention consisting of:~1. a tape-recorded session with the patient using the DT question protocol~2. Transcription of the interview, which is then edited~3. A session where the edited transcript is returned to the patient who can give it to family members or friends.~If needed, one or more sessions are added. Dt allows the patient to give voice to the matters of importance concerning himself and his loved ones. Its purpose is to enhance sense of meaning, purpose and worth. It also gives the opportunity to leave something behind to be remembered by.
Study: NCT01722357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: Participants are provided with Omron Model HJ-151 pedometers and given instruction on how to use the pedometer to set goals for increasing physical activity. They are given diaries to track their daily step counts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: Participants are provided with Omron Model HJ-151 pedometers and given instruction on how to use the pedometer to set goals for increasing physical activity. They are given diaries to track their daily step counts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Counseling
Description: Manualized cognitive behavioral treatment program including goal setting, adding exercise throughout the day, physical limitations/injuries, maintaining motivation, benefits of exercise, FITT principles, exercise as recreation, and restructuring thoughts related to activity.
Study: NCT00305734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03528590

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: size 3 i-gel supraglottic airway device
Description: Use size 3 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: size 4 i-gel supraglottic airway device
Description: Use size 4 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
Study: NCT06280053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HealiAid Collagen Wound Dressing
Description: HealiAid is an absorbable collagen wound dressing. It is fabricated by fibrous collagen matrix, in which the collagen is purified from bovine Achilles tendons. HealiAid can be applied easily by covering directly to the clean wound sites.
Study: NCT02836080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Collaborative Care Team (ICCT)
Description: An integrated, collaborative pathway of needs-based services. ICCTs will offer a wide variety of services, including Solution-Focused Brief Therapy (SFBT) on a scheduled and walk-in basis, care navigators, various clinician-guided interventions, psychiatry, nurse practitioner services, access to primary care, and peer support, all co-located in youth-friendly, community-based clinics. For each intervention, standardized intervention protocols will be used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Standard out-patient treatment provided at each participating hospital site. This typically entails referral to a psychiatrist at the participating hospital, who will provide assessment and treatment, with referral to appropriate services, guided by local treatment protocols.
Study: NCT03700346

Intervention type: DEVICE
Group type: OTHER
Intervention: microdialysis
Description: Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained by using muscle microdialysis

Intervention type: DEVICE
Group type: OTHER
Intervention: microdialysis
Description: Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained by using muscle microdialysis
Study: NCT04244721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preschool Autism Communication Therapy (PACT)
Description: Professionals guide parents in the PACT therapy by videoconference. Sessions between parent and professionals are every 15 days for 6 months. Each session lasts one hour. At the end of the 12 sessions, additional booster sessions (one session per month over 6 months) will allow parents to maintain their skills. Parents will use therapy with their children in daily home practice. The aims of PACT therapy is to improve synchrony in the communication between the child and the parents. Improvement of the synchrony will mediate the decrease of autism symptoms of the child.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: Children will receive therapies available in the community as speech language therapist or occupational therapist.
Study: NCT03912155

Intervention type: OTHER
Intervention: Multi-scale analysis of physiological brain networks
Description: It will be simultaneously record the surface EEG, the MEG and in patients only the intracerebral EEG (SEEG). In the case of SEEG with micro contacts, these additional signals will also be recorded in parallel and will provide greater sensitivity to high frequency activities. The physiological networks will be studied in patients thanks to stimulations (external or intracerebral) carried out within the framework of the functional cartography, and the pathological networks thanks to measures in state of rest. For external stimulation protocols, it will be constitute a reference base in MEG and EEG alone (non-invasive) on control subjects.

Intervention type: OTHER
Intervention: Multi-scale analysis of physiological brain networks
Description: It will be simultaneously record the surface EEG, the MEG and in patients only the intracerebral EEG (SEEG). In the case of SEEG with micro contacts, these additional signals will also be recorded in parallel and will provide greater sensitivity to high frequency activities. The physiological networks will be studied in patients thanks to stimulations (external or intracerebral) carried out within the framework of the functional cartography, and the pathological networks thanks to measures in state of rest. For external stimulation protocols, it will be constitute a reference base in MEG and EEG alone (non-invasive) on control subjects.
Study: NCT02066805

Intervention type: DRUG
Intervention: Database assessment of off-label XGEVA use
Description: No intervention is planned during this study as it involves analyses of patient electronic records from Northern Jutland Region and Copenhagen
Study: NCT03499704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone + Alogliptin
Description: Pioglitazone and Alogliptin FDC tablets
Study: NCT01176890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: 1.2 pmol/kg/min GLP-1 will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: 1.2 pmol/kg/min GLP-1 will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied
Study: NCT03499704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin tablets.
Study: NCT01038440

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Safflower Oil
Description: One softgel consumed daily with food

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA
Description: Three different doses of EPA (0.5, 1.5 and 3.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
Study: NCT01310621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bovine surfactant
Description: * Dose of diluted surfactant : 20ml/kg~* Type :Bovine surfactant~* Phospholipid concentration: 5 mg/ml~* Number of lavages to be given: 2 (10ml/kg each)
Study: NCT04067544

Intervention type: DEVICE
Group type: OTHER
Intervention: Acupuncture
Description: The manualized acupuncture treatment (AT) intervention will be designed by Dr. Budhathoki and Dr. Taylor-Swanson and administered by Dr. Budhathoki and members of Huntsman acupuncture team. Ten sessions of AT will be delivered: twice per week for 2 weeks, thereafter once per week for six weeks, with a total of 9 treatments during a two-month course. Each session will last 45-60 minutes, with acupuncture needles retained 30-40 minutes. A minimum of 8 treatments must be received by each participant with no more than 9 days' gap between treatments permitted. Concurrent medications are allowed as prescribed and will be tracked in the study and analyzed as potential confounders.~Participants in the study will undergo study interview and fMRI at the following two time points: within 9 days after baseline following enrollment and within one week of acupuncture treatment completion.
Study: NCT01176890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: 1.2 pmol/kg/min GLP-1 will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline (isotonic NaCl) will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline (isotonic NaCl) will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline (isotonic NaCl) will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied
Study: NCT02623699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofersen
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofersen
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofersen
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofersen
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofersen
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofersen
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofersen
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofersen
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofersen
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT00439894

Intervention type: PROCEDURE
Intervention: Blood draw
Description: blood draw at baseline, week 12 and week 24
Study: NCT02371018

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nepro
Description: Patients will be asked to consume a single 8 oz can of Nepro

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nepro
Description: Patients will be asked to consume a single 8 oz can of Nepro
Study: NCT01279980

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Description: Epidural analgesia inserted prior to surgery to stay in until at least the second postoperative day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local anaesthetic wound catheter
Description: The catheter will be used to infuse the wound with local anaesthetic for 48 hours post op.